Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma.
Harper G HubbelingDoris LeithnerEmily A SilvermanJessica R FlynnSean M DevlinGunjan L ShahBeatrice FregoneseBeatriz WillsAkshay S BedmuthaAna Alarcon TomasAllison ParascondolaAmethyst SaldiaIvan LandegoCarla HajjAlexander P BoardmanParastoo Bahrami DahiArnab GhoshSergio A GiraltRichard J LinJae H ParkMichael ScordoGilles Andre SallesJoachim YahalomMaria Lia PalombaHeiko SchöderMiguel-Ángel PeralesRoni ShouvalBrandon S ImberPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This is the first study to use radiomics to quantify disease burden pre- and post-BT in a large real world LBCL cohort. We demonstrate that effective BT can enable initially high-disease burden patients to achieve post-CART outcomes comparable to low-disease burden patients.